Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
WL Drew, RC Miner, GI Marousek, S Chou - Journal of clinical virology, 2006 - Elsevier
BACKGROUND: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance
S Chou, LC Van Wechel… - The Journal of infectious …, 2007 - academic.oup.com
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical
antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV …
antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV …
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir
S Chou - Antimicrobial agents and chemotherapy, 2009 - Am Soc Microbiol
In vitro resistance to maribavir (MBV), a cytomegalovirus UL97 kinase inhibitor currently in
clinical trials, is known to result from viral UL97 mutations that confer moderate to high-level …
clinical trials, is known to result from viral UL97 mutations that confer moderate to high-level …
[HTML][HTML] Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection
S Chou, J Wu, K Song, T Bo - Antiviral research, 2019 - Elsevier
In a Phase 2 clinical trial, 120 subjects with cytomegalovirus (CMV) infection refractory or
resistant to standard therapy were randomized equally to 3 doses of oral maribavir …
resistant to standard therapy were randomized equally to 3 doses of oral maribavir …
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
S Chou, M Hakki, S Villano - Antiviral research, 2012 - Elsevier
Resistance to the experimental human cytomegalovirus (CMV) UL97 kinase inhibitor
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
S Chou - Reviews in medical virology, 2008 - Wiley Online Library
Mutations in the human CMV UL97 kinase gene are a major mechanism of viral resistance
to two anti‐CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used …
to two anti‐CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used …
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir
S Chou, GI Marousek, AE Senters, MG Davis… - Journal of …, 2004 - Am Soc Microbiol
Previous drug selection experiments resulted in the isolation of a human cytomegalovirus
(CMV) UL97 phosphotransferase mutant resistant to the benzimidazole compound maribavir …
(CMV) UL97 phosphotransferase mutant resistant to the benzimidazole compound maribavir …
Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection
S Chou, K Song, J Wu, T Bo… - The Journal of infectious …, 2022 - academic.oup.com
Background In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant
S Chou, GI Marousek - Journal of virology, 2008 - Am Soc Microbiol
ABSTRACT A human cytomegalovirus (CMV) UL54 pol exonuclease domain II mutation,
D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance …
D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance …
[HTML][HTML] Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
A Schubert, K Ehlert, S Schuler-Luettmann… - BMC infectious …, 2013 - Springer
Background Human cytomegalovirus infections are still significant causes of morbidity and
mortality in transplant recipients. The use of antiviral agents is limited by toxicity and …
mortality in transplant recipients. The use of antiviral agents is limited by toxicity and …